卵巢癌患者肿瘤细胞减灭术异体输血危险因素分析及预测模型构建

曹嘉 ,  陈文燕 ,  马盼盼 ,  赵晋 ,  唐红悦 ,  刘建辉 ,  耿瑞丽

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (8) : 1026 -1032.

PDF (1445KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (8) : 1026 -1032. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.08.005
论著

卵巢癌患者肿瘤细胞减灭术异体输血危险因素分析及预测模型构建

作者信息 +

Analysis of risk factors for allogeneic blood transfusion and construction of a prediction model in patients with ovarian cancer undergoing cytoreductive surgery

Author information +
文章历史 +
PDF (1478K)

摘要

目的 探讨卵巢癌患者肿瘤细胞减灭术围手术期异体输血的独立危险因素,并构建预测模型,为临床精准评估输血风险、优化围手术期血液管理提供依据。方法 回顾性收集 2020 年 1 月至 2025 年 12 月在本院接受卵巢癌肿瘤细胞减灭术的 156 例患者临床资料,按围手术期是否接受异体输血分为输血组(n = 51)与未输血组(n = 105),采用 1 ∶1倾向性得分匹配(PSM)校正混杂因素。计量资料采用独立样本 t 检验或 Mann-Whitney U 检验,计数资料采用 χ2 检验;将单因素分析 P<0. 05 的变量纳入二元 Logistic 回归进行多因素分析,确定独立危险因素。基于独立危险因素构建围手术期异体输血风险预测列线图模型,采用 Bootstrap 法(100 次抽样)开展内部校准验证,ROC 曲线评估区分效能,决策曲线分析(DCA)评价模型临床净获益。结果 倾向性匹配后两组基线资料均衡可比。多因素 Logistic 回归分析显示,术前凝血酶原时间(PT)(OR = 2. 666,95%CI 1. 249 ~ 5. 693,P = 0. 011)、术前血红蛋白(Hb)(OR= 0. 953,95%CI 0. 923~0. 984,P= 0. 003)、术中出血量(OR = 1. 004,95%CI 1. 001 ~ 1. 006,P = 0. 004)、术前贫血分级(OR= 3. 052,95%CI 1. 007~9. 252,P= 0. 049)是围手术期异体输血的独立影响因素。基于上述 4 个因素构建的列线图模型整体显著(LRχ2 = 58. 617,P<0. 001),内部校准曲线显示模型预测概率与实际概率一致性良好(平均绝对误差= 0. 042);ROC 曲线下面积(AUC)为 0. 890,提示模型具有良好的区分效能;DCA 显示 0~ 0. 45 风险阈值区间内模型临床净收益优于统一输血/ 不输血策略。结论 术中出血量、术前 PT、术前 Hb、术前贫血分级是卵巢癌肿瘤细胞减灭术患者围手术期异体输血的独立危险因素。基于上述因素构建的列线图模型预测效能良好,且具备临床分层决策价值,可为临床对高危患者实施个体化血液管理、降低不必要输血率提供参考。

Abstract

Objective To explore the independent risk factors of allogeneic blood transfusion during perioperative period of cytoreductive surgery in patients with ovarian cancer, and to construct a predictive model to facilitate clinical risk assessment and optimize perioperative blood management. Methods Clinical data of 156 patients who underwent cytoreductive surgery for ovarian cancer in our hospital from January 2020 to December 2025 were retrospectively collected. The patients were divided into transfusion group (n= 51) and non-transfusion group (n= 105) according to whether they received allogeneic blood transfusion during perioperative period. The 1 ∶1 propensity score matching (PSM) was used to correct the confounding factors. Independent sample t test or Mann-Whitney U test was used for measurement data, and chisquare test was used for enumeration data. Variables with P<0. 05 in univariate analysis were included in binary logistic regression for multivariate analysis to determine independent risk factors. A nomogram model for perioperative allogeneic blood transfusion risk prediction was constructed based on independent risk factors. Bootstrap method (100 samples) was used for internal calibration verification. ROC curve was used to evaluate the discrimination efficiency, and decision curve analysis (DCA) was used to evaluate the clinical net benefit of the model. Results After propensity matching, the baseline data of the two groups were balanced and comparable. Multivariate logistic regression analysis showed that preoperative prothrombin time (PT)(OR= 2. 666,95%CI 1. 249 ~ 5. 693,P = 0. 011), preoperative hemoglobin (Hb) (OR = 0. 953,95% CI 0. 923 ~ 0. 984,P= 0. 003), intraoperative blood loss (OR= 1. 004,95%CI 1. 001-1. 006,P = 0. 004), preoperative anemia grade (OR= 3. 052,95%CI 1. 007-9. 252,P = 0. 049) were independent influencing factors of perioperative allogeneic blood transfusion. The nomogram model based on the above four factors was significant (LR χ2 = 58. 617, P<0. 001), and the internal calibration curve showed that the predicted probability of the model was in good agreement with the actual probability (mean absolute error= 0. 042). The area under the ROC curve (AUC) was 0. 890, indicating good discrimination efficiency. DCA showed that the clinical net benefit of the model was better than that of the unified transfusion/ non-transfusion strategy in the 0-0. 45 risk threshold range. Conclusion Intraoperative blood loss, preoperative PT, preoperative Hb and preoperative anemia grade are independent risk factors for perioperative allogeneic blood transfusion in patients undergoing cytoreductive surgery for ovarian cancer. The nomogram model based on the above factors has good predictive efficacy and clinical hierarchical decision-making value, which can provide reference for clinical implementation of individualized blood management for high-risk patients and reduction of unnecessary blood transfusion rate.

关键词

卵巢癌 / 肿瘤细胞减灭术 / 异体输血 / 危险因素 / 围手术期血液管理

Key words

ovarian cancer / cytoreductive surgery / allogeneic blood transfusion / risk factors / perioperative blood management

引用本文

引用格式 ▾
曹嘉,陈文燕,马盼盼,赵晋,唐红悦,刘建辉,耿瑞丽. 卵巢癌患者肿瘤细胞减灭术异体输血危险因素分析及预测模型构建[J]. 中国输血杂志, 2026, 39(8): 1026-1032 DOI:10.13303/j.cjbt.issn.1004-549x.2026.08.005

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

刘薇,徐宵寒,虞雪融. 卵巢癌患者肿瘤细胞减灭术前低蛋白血症与围术期异体红细胞输注风险的相关性:单中心回顾性队列研究[J].协和医学杂志,2024,15(4):456-462.

[2]

TSOLAKIDIS D, CHATZISTAMATIOU K, MARKOPOULOU E, et al. Utilization of ligasure maryland jaw open sealer/ divider with nanocoating improves perioperative parameters in women with advanced ovarian cancer subjected to cytoreductive surgery[J].J Clin Med, 2025, 14(17):6293.

[3]

WANG H, LI Y, YANG Z, et al. Surgical treatment and prognosis in patients with intestinal metastases originated from advanced epithelial ovarian cancer[J].Front Oncol,2026,16:1760552-1760552.

[4]

CHAN V, SHUMILAK G, MALHOTRA K A, et al. Allogeneic transfusion-related adverse events in pediatric idiopathic scoliosis surgery[J].J Pediatr Orthop Soc North Am,2026,16:100410-100410.

[5]

FORTIER B G, GIEN T L, CHAN C W, et al. The impact of perioperative transfusions on the oncologic outcomes of patients with ovarian cancer:A population-based study[J].J Surg Oncol, 2024, 130(8):1717-1724.

[6]

PRESCOTT S L, VERGOTE I, SUN C C, et al. Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer:evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort[J].Int J Gynecol Cancer, 2023, 33(1):1-9.

[7]

陈小军,陈小祥,申震,等. 老年卵巢癌患者围手术期管理专家共识(2024 年版)[J].中国实用妇科与产科杂志,2024,40(7):729-736.

[8]

CHEN X J, CHEN X X, SHEN Z, et al. Expert consensus on perioperative management of elderly patients with ovarian cancer (2024 edition)[J].Chin J Pract Gynecol Obstet 2024, 40(7):729-736.

[9]

崔广霞,陈麟凤,白文佩,等. 妇科恶性肿瘤围术期患者血液管理专家共识(2025 年版)[J].中国实用妇科与产科杂志,2025,41(3):316-323.

[10]

CUI G X, CHEN L F, BAI W P, et al. Expert consensus on perioperative blood management in patients with gynecologic malignancies (2025 edition)[J].Chin J Pract Gynecol Obstet, 2025,41(3):316-323.

[11]

TASCI E A, KıLıÇ F, ÜNSAL M, et al. Anastomotic leakage after rectosigmoid resection with primary anastomosis during cytoreductive surgery for advanced high-grade serous ovarian cancer:risk factors and oncologic outcomes.[J].J Ovarian Res,2026,19(1):84.

[12]

SINGH S,TANTRY S U,BLIDEN K, et al. Restrictive versus liberal transfusion in symptomatic coronary artery disease and myocardial infarction: a meta-analysis of randomized controlled trials.[J].Am J Ther,2024,31(6):e677-e682.

[13]

WOOD K M, EMMANUEL S, BROCK P, et al. Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery[J].BMC Cancer, 2018, 18(1):1041.

[14]

REN W, YAO J. Effect of restrictive blood transfusion strategy on perioperative prognosis in elderly orthopedic surgery patients with preoperative anemia.[J].Ann Ital Chir,2025,96(9):1190-1197.

[15]

钟昌瑞,傅春花,邱小兰. 全髋关节置换术中输血的关联因素分析[J].中国输血杂志,2021,34 (3):249-252.

[16]

ZHONG C R, FU C H, QIU X L. Analysis of related factors of blood transfusion in total hip arthroplasty[J].Chin J Blood Transfusions, 2021,34(3):249-252.

[17]

张莉蓉. 全膝和全髋关节置换术异体输血发生率及危险因素分析[J].中国药物与临床,2021,21 (22):3761-3763.

[18]

ZHANG L R. Analysis of the incidence and risk factors of allogeneic blood transfusion in total knee and total hip arthroplasty[J].Chin J Drugs Clin, 2021, 21 (22):3761-3763.

[19]

GALAAL K, VICKERY J P, MARQUES E, et al. The trial of intraoperative cell salvage versus transfusion in ovarian cancer (tic toc): results of a randomized controlled feasibility study[J].Cancers,2026,18(4):711-711.

[20]

FRAMARINI M, D′ACAPITO F, LIPPOLIS V P, et al. Expanding the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy:A multicenter study on uncommon peritoneal malignancies.[J].World J Clin Oncol,2025,16(12):112443.

[21]

YUAN X J, MAO C, XU L F, et al. Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer:A randomized controlled clinical trial[J].Acta Obstetricia et Gynecologica Scandinavica,2023, 102(7):839-846.

[22]

王静,胡诗音,龚倩,等. 基于 Logistic 回归和决策树构建卵巢癌病人营养风险预测模型[J].护理研究,2025,39(22):3751-3756.

[23]

WANG J, HU S Y, GONG Q, et al. The nutritional risk prediction model of ovarian cancer patients was constructed based on Logistic regression and decision tree[J].Chin Nurs Res, 2025,39 (22):3751-3756.

[24]

ANTONIO M, ELISABETTA S, FABRIZIO L, et al. Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence:feasibility and technique[J].BMC Surg,2021,21(1):380-380.

[25]

朱逢佳,黄筱竑. 围手术期同种异体输血对晚期上皮性卵巢癌预后的潜在影响[J].中国药物与临床,2020,20(7):1161-1163.

[26]

ZHU F J, HUANG X H. The potential impact of perioperative allogeneic blood transfusion on the prognosis of advanced epithelial ovarian cancer[J].Chin J Drugs Clin, 2020,20(7):1161-1163.

[27]

蒋国伟,袁红斌,蒋鑫. 术中自体血回输用于肿瘤患者的研究进展[J].临床麻醉学杂志,2023,39 (10):1088-1092.

[28]

JIANG G W, YUAN H B, JIANG X. Research progress of intraoperative autologous blood transfusion for cancer patients[J].J Clin Anesthesiol, 2023,39(10):1088-1092.

[29]

王东红,赵永强,李文娟,等. 恶性肿瘤患者术中自体血回输的临床应用进展[J].中国医药导报,2023,20(12):48-51.

[30]

WANG D H, ZHAO Y Q, LI W J, et al. Clinical application progress of intraoperative autologous blood transfusion in patients with malignant tumors[J].Chin Med Herald, 2023,20 (12):48-51.

基金资助

河北省医学科学研究课题计划(20190353)

AI Summary AI Mindmap
PDF (1445KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉